Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to $5.6 million.

  • Vanda Pharmaceuticals' Change in Receivables rose 57096.39% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year decrease of 4172.32%. This contributed to the annual value of $13.0 million for FY2024, which is 174045.26% up from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Change in Receivables is $5.6 million, which was up 57096.39% from $353000.0 recorded in Q2 2025.
  • Vanda Pharmaceuticals' Change in Receivables' 5-year high stood at $9.1 million during Q2 2023, with a 5-year trough of -$9.0 million in Q4 2021.
  • Over the past 5 years, Vanda Pharmaceuticals' median Change in Receivables value was $1.5 million (recorded in 2021), while the average stood at $1.1 million.
  • Data for Vanda Pharmaceuticals' Change in Receivables shows a peak YoY increase of 66242.27% (in 2023) and a maximum YoY decrease of 82984.82% (in 2023) over the last 5 years.
  • Vanda Pharmaceuticals' Change in Receivables (Quarter) stood at -$9.0 million in 2021, then soared by 145.16% to $4.1 million in 2022, then grew by 18.79% to $4.8 million in 2023, then dropped by 8.37% to $4.4 million in 2024, then increased by 25.68% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $353000.0 for Q2 2025, and -$2.5 million during Q1 2025.